Integrated Profiling Identifies CCNA2 as a Potential Biomarker of Immunotherapy in Breast Cancer

References

• Liao WS, Ho Y, Lin YW, et al. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Acta Biomater. 2019;86:395–405. doi:10.1016/j.actbio.2019.01.025
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Tsuchida J, Nagahashi M, Takabe K, Wakai T. Clinical impact of sphingosine-1-phosphate in breast cancer. Mediators Inflamm. 2017;2017:2076239. doi:10.1155/2017/2076239
   PubMed Web of Science ®Google Scholar
• Aumeeruddy MZ, Mahomoodally MF. Combating breast cancer using combination therapy with 3 phytochemicals: piperine, sulforaphane, and thymoquinone. CA Cancer Soc. 2019;125(10):1600–1611.
   Google Scholar
• Wang J, Zhou P. New approaches in CAR-T cell immunotherapy for breast cancer. Adv Exp Med Biol. 2017;1026:371–381.
   PubMed Web of Science ®Google Scholar
• Hong BS, Ryu HS, Kim N, et al. Tumor suppressor miRNA-204-5p regulates growth, metastasis, and immune microenvironment remodeling in breast cancer. Cancer Res. 2019;79(7):1520–1534. doi:10.1158/0008-5472.CAN-18-0891
   PubMed Web of Science ®Google Scholar
• Hadadi E, Taylor W, Li XM, et al. Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice. Nat Commun. 2020;11(1):3193. doi:10.1038/s41467-020-16890-6
   PubMed Web of Science ®Google Scholar
• Savas D, Tzankov A, Muenst SE. Role of the tumor microenvironment in breast cancer. Pathobiology. 2015.
   Web of Science ®Google Scholar
• Di Cosimo S. Advancing immunotherapy for early-stage triple-negative breast cancer. Lancet. 2020;396(10257):1046–1048. doi:10.1016/S0140-6736(20)31962-0
   PubMed Web of Science ®Google Scholar
• Deng J, Thennavan A, Shah S, et al. Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. Breast Cancer Res Treat. 2020;185(1):85–94. doi:10.1007/s10549-020-05936-4
   PubMed Web of Science ®Google Scholar
• Mansour M, Teo ZL, Luen SJ, Loi S. Advancing immunotherapy in metastatic breast cancer. Curr Treat Options Oncol. 2017;18(6):35. doi:10.1007/s11864-017-0478-9
   PubMed Web of Science ®Google Scholar
• Budczies J, Bockmayr M, Denkert C, et al. Classical pathology and mutational load of breast cancer – integration of two worlds. J Pathol Clin Res. 2015;1(4):225–238. doi:10.1002/cjp2.25
   PubMedGoogle Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a Phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–867. doi:10.1200/JCO.2011.41.0902
   PubMed Web of Science ®Google Scholar
• Tang S, Ning Q, Yang L, Mo Z, Tang S. Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 2020;86:106700. doi:10.1016/j.intimp.2020.106700
   PubMed Web of Science ®Google Scholar
• Song L, Chen X, Mi L, et al. Icariin-induced inhibition of SIRT6/NF-kappaB triggers redox mediated apoptosis and enhances anti-tumor immunity in TNBC. Cancer Sci. 2020;111(11):4242–4256. doi:10.1111/cas.14648
   PubMed Web of Science ®Google Scholar
• Fiorini E, Veghini L, Corbo V. Modeling cell communication in cancer with organoids: making the complex simple. Front Cell Dev Biol. 2020;8:166. doi:10.3389/fcell.2020.00166
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113–1120. doi:10.1038/ng.2764
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qiu P, Ji Y. TCGA-assembler: open-source software for retrieving and processing TCGA data. Nat Methods. 2014;11(6):599–600. doi:10.1038/nmeth.2956
   PubMed Web of Science ®Google Scholar
• Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507. doi:10.1126/science.aan2507
   PubMed Web of Science ®Google Scholar
• Baughman JM, Perocchi F, Girgis HS, et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature. 2011;476(7360):341–345. doi:10.1038/nature10234
   PubMed Web of Science ®Google Scholar
• Radulescu E, Jaffe AE, Straub RE, et al. Identification and prioritization of gene sets associated with schizophrenia risk by co-expression network analysis in human brain. Mol Psychiatry. 2020;25(4):791–804. doi:10.1038/s41380-018-0304-1
   PubMed Web of Science ®Google Scholar
• Liang H, Bai Y, Wang H, Yang X. Identification of LncRNA prognostic markers for ovarian cancer by integration of co-expression and CeRNA network. Front Genet. 2020;11:566497. doi:10.3389/fgene.2020.566497
   PubMed Web of Science ®Google Scholar
• Huang H, Tan M, Zheng L, et al. Prognostic implications of the complement protein C1Q and its correlation with immune infiltrates in osteosarcoma. Onco Targets Ther. 2021;14:1737–1751. doi:10.2147/OTT.S295063
   PubMed Web of Science ®Google Scholar
• Qi J, Liu Y, Hu J, et al. Identification of FPR3 as a unique biomarker for targeted therapy in the immune microenvironment of breast cancer. Front Pharmacol. 2020;11:593247. doi:10.3389/fphar.2020.593247
   PubMed Web of Science ®Google Scholar
• Ding W, Chen G, Shi T. Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis. Epigenetics. 2019;14(1):67–80. doi:10.1080/15592294.2019.1568178
   PubMed Web of Science ®Google Scholar
• Gao T, Han Y, Yu L, Ao S, Li Z, Ji J. CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. PLoS One. 2014;9(3):e91771.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Li Z, Xie J, et al. MiRNA-224-5p inhibits autophagy in breast cancer cells via targeting Smad4. Biochem Biophys Res Commun. 2018;506(4):793–798. doi:10.1016/j.bbrc.2018.10.150
   PubMed Web of Science ®Google Scholar
• Guha M, Srinivasan S, Raman P, et al. Aggressive triple negative breast cancers have unique molecular signature on the basis of mitochondrial genetic and functional defects. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt A):1060–1071. doi:10.1016/j.bbadis.2018.01.002
   PubMed Web of Science ®Google Scholar
• Hollern DP, Andrechek ER. A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer. Breast Cancer Res. 2014;16(3):R59. doi:10.1186/bcr3672
   PubMed Web of Science ®Google Scholar
• Liu Y, Xie X, Hou X, et al. Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis. J Nanobiotechnology. 2020;18(1):83. doi:10.1186/s12951-020-00638-x
   PubMed Web of Science ®Google Scholar
• Tseng YJ, Huang CE, Wen CN, et al. Predicting breast cancer metastasis by using serum biomarkers and clinicopathological data with machine learning technologies. Int J Med Inform. 2019;128:79–86. doi:10.1016/j.ijmedinf.2019.05.003
   PubMed Web of Science ®Google Scholar
• Gallego-Ortega D, Ledger A, Roden DL, et al. ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells. Plos Biol. 2015;13(12):e1002330. doi:10.1371/journal.pbio.1002330
   PubMed Web of Science ®Google Scholar
• Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res. 2020;10(4):1045–1067.
   PubMed Web of Science ®Google Scholar
• Panagi M, Voutouri C, Mpekris F, et al. TGF-beta inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics. 2020;10(4):1910–1922. doi:10.7150/thno.36936
   PubMed Web of Science ®Google Scholar
• Desai D, Shende P. Strategic aspects of NPY-based monoclonal antibodies for diagnosis and treatment of breast cancer. Curr Protein Pept Sci. 2020;21(11):1097–1102. doi:10.2174/1389203721666200918151604
   PubMed Web of Science ®Google Scholar
• Lyu L, Yao J, Wang M, et al. Overexpressed pseudogene HLA-DPB2 promotes tumor immune infiltrates by regulating HLA-DPB1 and indicates a better prognosis in breast cancer. Front Oncol. 2020;10:1245. doi:10.3389/fonc.2020.01245
   PubMed Web of Science ®Google Scholar
• Goff SL, Danforth DN. The role of immune cells in breast tissue and immunotherapy for the treatment of breast cancer. Clin Breast Cancer. 2020;21(1):e63–e73. doi:10.1016/j.clbc.2020.06.011
   PubMed Web of Science ®Google Scholar
• von der Lippe GH, Lien T, Tekpli X, et al. Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer. Int J Cancer. 2020.
   Web of Science ®Google Scholar
• Zerdes I, Sifakis EG, Matikas A, et al. Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. Mol Oncol. 2020;14(5):951–963. doi:10.1002/1878-0261.12654
   PubMed Web of Science ®Google Scholar
• Lu Y, Yang G, Xiao Y, et al. Upregulated cyclins may be novel genes for triple-negative breast cancer based on bioinformatic analysis. Breast Cancer. 2020;27(5):903–911. doi:10.1007/s12282-020-01086-z
   PubMed Web of Science ®Google Scholar